Project Grant HT9425261E217
Award Date 7/1/26
Completion Date 6/30/29
Dollars Obligated $907K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded University of Colorado-Denver $842,067 under the Military Medical Research and Development program (CFDA 12.420) for the project "Overcoming Resistance to BRAF-Directed Therapy in Advanced Thyroid Cancer." The award, initiated July 1, 2026, with completion targeted for June 30, 2029, supports basic and applied biomedical research designed to advance innovative medical solutions for both military service members...
- Federal Grant Award Summary The University of Colorado-Denver received a $624,000 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period of July 1, 2025, through June 30, 2027. The award supports research focused on targeting androgen receptors as a novel therapeutic strategy for advanced thyroid cancer. This research initiative aligns with the DHA's broader mission to transform healthcare for service members...
- Federal Grant Award Summary The Defense Health Agency awarded the University of Colorado-Denver a $904,982 Project Grant effective June 1, 2026, through May 31, 2029, under the Military Medical Research and Development program (CFDA 12.420). The award supports research to investigate the use of unconventional immune cells in treating rare melanomas and understanding immunotherapy resistance. This research initiative aligns with the Defense Health Agency's mission to advance innovative biomedical...
- Federal Grant Award Summary The University of Colorado-Denver received a $1.18 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for a three-year performance period from June 1, 2026, through May 31, 2029. The award supports research on the use of unconventional immune cells to treat rare melanomas and understand immunotherapy resistance. This research initiative aligns with the DHA's mission to advance biomedical...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded University of Colorado-Denver a $1.4M Project Grant effective July 1, 2026, through June 30, 2029, under the Military Medical Research and Development program (CFDA 12.420). The award supports research focused on enhancing Linker for Activation of T cells (LAT) activity in chimeric antigen receptor (CAR) T cell therapies for Ewing sarcoma treatment. This research initiative represents DHA's commitment to advancing innovative...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $672,000 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2027. The award supports research investigating a novel synthetic lethal vulnerability in anaplastic thyroid cancer through inhibition of one-carbon metabolism. This two-year research initiative will be conducted at the institution's...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Trustees of Columbia University in the City of New York's Health Sciences Division a $1.645 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2025, through June 30, 2028. The award supports research on treating HER2 therapy-resistant brain metastasis using antidepressants, conducted at Columbia's Health Sciences Division facility in New York, NY. This project...
- Federal Project Grant Award Summary Columbia University's Health Sciences Division received a $750,000 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) with a performance period from July 1, 2026 through June 30, 2029. The award funds research to identify novel therapeutic targets that overcome treatment resistance in triple-negative breast cancer (TNBC), a particularly aggressive form of cancer with limited...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded a $2.87M Project Grant to The Regents of the University of Colorado (doing business as University of Colorado-Denver) on September 1, 2025, under the Military Medical Research and Development program (CFDA 12.420). The four-year award, which extends through August 31, 2029, supports research evaluating the Clinical, Biomarkers, Imaging, and Modifiers (CBI-M) classification system for traumatic brain injury (TBI). This research...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Washington University a $699,751 Project Grant under the Military Medical Research and Development program (CFDA 12.420) on May 1, 2026, with a completion date of April 30, 2029. The award funds research to unveil mechanisms and develop innovative therapeutic interventions targeting ESR1-CCDC170 fusions in clinically aggressive, endocrine-resistant, and metastatic breast cancers. This research initiative represents the DHA's...